このエントリーをはてなブックマークに追加
ID 55858
JaLCDOI
フルテキストURL
Thumnail 72_2_175.pdf 1.94 MB
著者
Hirata, Takeshi Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Hanamoto, Masanori Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Ogura, Kazuma Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Hayashi, Nobuki Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Takamura, Kosuke Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Edamura, Kohei Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Ebara, Shin Department of Urology, Hiroshima City Hiroshima Citizens Hospital
Saika, Takashi Department of Urology, Ehime University Hospital
抄録
There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second-line or salvage therapy for advanced UC.
キーワード
urothelial carcinoma
gemcitabine
cisplatin
paclitaxel
second-line
salvage
Amo Type
Original Article
発行日
2018-04
出版物タイトル
Acta Medica Okayama
72巻
2号
出版者
Okayama University Medical School
開始ページ
175
終了ページ
179
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID